Neovacs S.A Kurs/ Buchwert
Was ist das Kurs/ Buchwert von Neovacs S.A?
Kurs/ Buchwert von Neovacs S.A. ist 2.20
Was ist die Definition von Kurs/ Buchwert?
Kurs-Buchwert-Verhältnis repräsentiert das Verhältnis zwischen dem Aktienwert eines Unternehmens und dem Buchwert pro Aktie.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Kurs/ Buchwert von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Neovacs S.A
Was macht Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Unternehmen mit kurs/ buchwert ähnlich Neovacs S.A
- SNC-Lavalin hat Kurs/ Buchwert von 2.20
- AYM Syntex hat Kurs/ Buchwert von 2.20
- SpineGuard SA hat Kurs/ Buchwert von 2.20
- China Feihe hat Kurs/ Buchwert von 2.20
- FireFox Gold hat Kurs/ Buchwert von 2.20
- Sioen Industries NV hat Kurs/ Buchwert von 2.20
- Neovacs S.A hat Kurs/ Buchwert von 2.20
- Sutro Biopharma Inc hat Kurs/ Buchwert von 2.20
- Sunrise Resources plc hat Kurs/ Buchwert von 2.20
- Videlio SA hat Kurs/ Buchwert von 2.20
- SNAM SpA hat Kurs/ Buchwert von 2.20
- Spirit Banner II Capital hat Kurs/ Buchwert von 2.20
- Amphastar Pharmaceuticals Inc hat Kurs/ Buchwert von 2.20